Sclerosing polycystic adenosis
Sclerosing polycystic adenosis (SPA) is a rare benign neoplasm that primarily affects the salivary glands. It was first described in 1996 by Smith et al. and is characterized by its resemblance to fibrocystic disease of the breast and sclerosing adenosis.
Epidemiology[edit]
SPA is a rare condition, with fewer than 100 cases reported in the literature. It can occur at any age but is most commonly diagnosed in middle-aged adults. There is no known gender predilection.
Pathology[edit]
SPA is characterized by a polycystic architecture, with cysts lined by a double layer of epithelial cells. The stroma is typically sclerotic, and there is often a lymphocytic infiltrate. The lesion can be unifocal or multifocal, and it can involve any of the major or minor salivary glands. The most commonly affected site is the parotid gland.
Clinical Presentation[edit]
Patients with SPA typically present with a slow-growing, painless mass. Some patients may experience pain or discomfort. On examination, the mass is usually firm and non-tender. SPA can be associated with Sjögren's syndrome and other autoimmune diseases.
Diagnosis[edit]
The diagnosis of SPA is typically made on histopathological examination of a biopsy specimen. Imaging studies such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) can be helpful in determining the extent of the disease and planning treatment.
Treatment[edit]
The treatment of choice for SPA is surgical excision. In some cases, where the disease is extensive or surgery is not feasible, radiotherapy may be considered.
Prognosis[edit]
The prognosis for patients with SPA is generally good. The disease is benign and does not metastasize. However, recurrence after surgical excision is common.
See Also[edit]
-
Low power H&E stained image of a parotid sclerosing polycystic adenoma
-
High power H&E stained image of a parotid sclerosing polycystic adenoma
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
